Vergleich

Dihydroartemisinin

ArtNr CS-5595-100mg
Hersteller ChemScene
Menge 100mg
Kategorie
Typ Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Similar products 71939-50-9
Lieferbar
Alternative Names
Dihydroqinghaosu; beta-Dihydroartemisinin; Artenimol
CAS
71939-50-9
Purity
>98%
Formula
C15H24O5
MWt
284.35
Solubility
DMSO : 41.67 mg/mL (146.54 mM; Need ultrasonic)
Clinical Information
Launched
Pathway
Autophagy; Anti-infection; NF-kappaB
Target
Autophagy; Parasite; NF-kappaB
Biological Activity
Dihydroartemisinin is a potent anti-malaria agent. IC50 & Target: RelA/p65[1]
Autophagy[1] In Vitro: Dihydroartemisinin (DHA) is an antimalarial agent. Dihydroartemisinin treatment effectively up-regulates the cytosolic RelA/p65 protein level and down-regulates the nuclear RelA/p65 protein level. Dihydroartemisinin blocks the nuclear translocation of RelA/p65 from the cytosol rather than suppressing RelA/p65 protein synthesis. Dihydroartemisinin induces autophagy in RPMI 8226 cells. Dihydroartemisinin suppresses NF-kappaB activation in RPMI 8226 cells. The NF-kappaB Dihydroartemisinin -binding activity is examined by EMSA assay. RPMI 8226 cells are exposed to various concentrations of Dihydroartemisinin (10, 20 and 40 uM) for 12 h, and TNF-alpha is introduced as a positive control for NF-kappaB activation. Dihydroartemisinin suppresses NF-kappaB activation in a dose-dependent manner in contrast with TNF-alpha[1]. Dihydroartemisinin (DHA) can enhance the anti-tumor effect of photodynamic therapy (PDT) on esophageal cancer cells, and cell viability is investigated using the MTT assay. Eca109 and Ec9706 cells are treated with Dihydroartemisinin (80 uM), PDT (25 and 20 J/cm2, respectively) or their combination. Single treatment with Dihydroartemisinin or PDT causes a 37+/-5% or 34+/-6% reduction in viability in Eca109 cells and a 33+/-7% or 34+/-6% reduction in Ec9706 cells, respectively. However, when PDT is combined with Dihydroartemisinin, the cell viability is reduced 59+/-6% or 61+/-7% in the cell lines, respectively[2]. In Vivo: Single oral doses of Dihydroartemisinin (at 200, 300, 400 or 600 mg/kg), given once on each of day 6-8 post-infection, reduce total-worm burdens by 69.2%-90.6% and female-worm burdens by 62.2%-92.2%, depending on dosage in the first experiment. Similar treatments given on day 34-36 post-infection reduce total-worm burdens by 73.9%-85.5% and female-worm burdens by 83.8%-95.3%[3].

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 100mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen